Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if JANX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
33 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
194 filers reported a long position in JANX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $171.9M | 11.2M | Unchanged |
| BlackRock, Inc. | $94.2M | 6.1M | +12.9% |
| Prosight Management, LP | $58.4M | 3.8M | +7.2% |
| STATE STREET CORP | $46.2M | 3M | +22% |
| FMR LLC | $37.1M | 2.4M | -4.8% |
| FEDERATED HERMES, INC. | $36.1M | 2.4M | +4,241.2% |
| Point72 Asset Management, L.P. | $30.6M | 2M | +72.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.5M | 1.9M | +2.5% |
| TCG Crossover Management, LLC | $27.5M | 1.8M | Unchanged |
| Alyeska Investment Group, L.P. | $25.3M | 1.6M | +2.9% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.